文献速递免疫规划

MenACYW-TT四价脑膜炎球菌结合疫苗在美国健康青少年中的II期随机免疫原性与安全性研究

A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States.
PubMed 文献 · Vaccine · 2020-03-21

在美国10-17岁未接种过脑膜炎球菌疫苗的健康青少年中开展的II期开放标签多中心随机研究,1715名参与者随机接种MenACYW-TT、MCV4-CRM、MenACYW-TT与Tdap及HPV4联合接种或仅接种Tdap和HPV4。MenACYW-TT对MCV4-CRM的免疫原性非劣效成立,且各血清群疫苗血清应答率均高于MCV4-CRM;与Tdap和HPV4联合接种时免疫原性和安全性相当。

要点

  • MenACYW-TT对MCV4-CRM的免疫原性非劣效成立(主要终点)。
  • MenACYW-TT与Tdap和HPV4联合接种对比单独接种的非劣效性成立(次要终点)。
  • MenACYW-TT各血清群疫苗血清应答率均高于MCV4-CRM,未报告疫苗相关严重不良事件。

核心结论

  • MenACYW-TT疫苗耐受性良好,产生的免疫应答非劣效于已获许可的MCV4-CRM疫苗。
  • 在未接种过脑膜炎球菌疫苗的青少年中,MenACYW-TT与或不与Tdap和HPV4疫苗同时接种时,免疫原性和安全性特征相当。

研究设计与样本

  • II期、开放标签、多中心随机研究(NCT02199691),在美国10-17岁未接种过脑膜炎球菌疫苗的健康青少年中开展。
  • 1715名参与者随机分配至接种MenACYW-TT、MCV4-CRM、MenACYW-TT与Tdap及HPV4联合接种、或仅接种Tdap和HPV4疫苗。
  • 主要目标为评估MenACYW-TT抗原的抗体应答是否非劣效于MCV4-CRM接种后的抗体应答。
  • 采用人补体血清杀菌试验(hSBA)测定脑膜炎球菌抗体滴度,时间点为基线及接种后30天(D30)。
  • 疫苗血清应答定义为基线滴度<1:8且接种后滴度≥1:8,或基线滴度≥1:8且接种后滴度≥4倍升高。

主要发现

  • MenACYW-TT对比MCV4-CRM的非劣效性成立(主要终点)。
  • MenACYW-TT与Tdap和HPV4联合接种对比单独接种MenACYW-TT的非劣效性成立(次要终点)。
  • MenACYW-TT的疫苗血清应答率高于MCV4-CRM,各血清群分别为:A群75.6% vs 66.4%;C群97.2% vs 72.6%;W群86.2% vs 66.6%;Y群97.0% vs 80.8%。
  • MenACYW-TT、MCV4-CRM以及Tdap和HPV4疫苗(与或不与MenACYW-TT联合接种)的安全性特征相当。
  • 未报告疫苗相关严重不良事件。

关键数值与推荐

  • 非劣效性判定:MenACYW-TT对比MCV4-CRM非劣效成立(主要终点)。
  • 非劣效性判定:MenACYW-TT与Tdap和HPV4联合接种对比单独接种MenACYW-TT非劣效成立(次要终点)。
  • 疫苗血清应答率:A群MenACYW-TT 75.6% vs MCV4-CRM 66.4%;C群97.2% vs 72.6%;W群86.2% vs 66.6%;Y群97.0% vs 80.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for use in individuals ≥6 weeks of age. We evaluated the safety and immunogenicity of MenACYW-TT when compared to a licensed quadrivalent conjugate meningococcal vaccine (Menveo®; MCV4-CRM; GlaxoSmithKline, Italy), and when co-administered with tetanus, diphtheria, acellular pertussis (Tdap) and human papilloma virus (HPV4) vaccines in healthy meningococcal vaccine-naïve adolescents (10-17 years old) in the United States of America. METHODS: In this pivotal Phase II, open-label, multicenter study, 1715 participants were randomized to receive MenACYW-TT, MCV4-CRM, MenACYW-TT co-administered with Tdap and HPV4, or Tdap and HPV4 vaccines alone (NCT02199691). The primary objective was to evaluate whether antibody responses to MenACYW-TT antigens were non-inferior to antibody responses after MCV4-CRM administration. Meningococcal antibody titers were determined using human complement serum bactericidal assay (hSBA) with titers measured at baseline, and 30 days post vaccination (D30). A vaccine seroresponse was defined as baseline titers <1:8 with post-vaccination titers ≥1:8 or baseline titers ≥1:8 with a ≥4-fold increase at post-vaccination. Safety data were collected up to six months post-vaccination. RESULTS: Non-inferiority was demonstrated for MenACYW-TT vs MCV4-CRM (primary endpoint), and for MenACYW-TT co-administered with Tdap and HPV4 vs MenACYW-TT alone (secondary endpoint). The vaccine seroresponse rate was higher with MenACYW-TT than with MCV4-CRM, for each serogroup: A: 75.6% vs 66.4%; C: 97.2% vs 72.6%; W: 86.2% vs 66.6%; Y: 97.0% vs 80.8%. The safety profiles of MenACYW-TT, MCV4-CRM, and Tdap and HPV4 vaccines, administered with or without MenACYW-TT, were comparable. There were no vaccine-related serious adverse events. CONCLUSIONS: The MenACYW-TT vaccine was well tolerated and generated an immune response that was non-inferior to the licensed MCV4-CRM vaccine. Immunogenicity and safety profiles were comparable when MenACYW-TT was administered with or without Tdap and HPV4 vaccines in meningococcal vaccine-naïve adolescents.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chang LJ, Hedrick J, Christensen S, et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020. PMID: 32209248. doi:10.1016/j.vaccine.2020.03.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。